Two-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)
Lebrikizumab治疗中重度特应性皮炎患者的两年疗效和安全性:一项长期扩展研究(ADjoin)
期刊:Dermatology and Therapy
影响因子:4.2
doi:10.1007/s13555-025-01452-9
Guttman-Yassky, Emma; Weidinger, Stephan; Simpson, Eric L; Gooderham, Melinda; Irvine, Alan D; Spelman, Lynda; Silverberg, Jonathan I; ElMaraghy, Hany; DeLuca-Carter, Louise; Piruzeli, Maria Lucia Buziqui; Hu, Chaoran; Yang, Fan Emily; Pierce, Evangeline; Bardolet, Laia; Thaçi, Diamant